Insuvil Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance the levels of incretin hormones, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. This dual action helps improve glycemic control without causing significant hypoglycemia or weight gain. Insuvil is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy when metformin is inappropriate or as combination therapy with other antidiabetic agents including metformin, sulfonylureas, or insulin. The recommended dosage is typically 50 mg twice daily, adjusted according to renal function and clinical response. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances, though it is generally well tolerated. Caution is advised in patients with renal impairment, and periodic monitoring of renal function is recommended. Insuvil should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Overall, Insuvil Tablet offers an effective and well-tolerated option for improving glycemic control in type 2 diabetes patients.